Tumour ploidy, response and survival in patients receiving endocrine therapy for advanced breast cancer. by Stuart-Harris, R. et al.
Br. J. Cancer (1985), 51, 573-576
Short Communication
Tumour ploidy, response and survival in patients receiving
endocrine therapy for advanced breast cancer
R. Stuart-Harris', D.W. Hedley', I.W. Taylor', A.L. Levene2 & I.E. Smith2
ILudwig Institutefor Cancer Research (Sydney Branch), Blackburn Building, University ofSydney, Sydney,
N.S. W. 2006, Australia; 2The Royal Marsden Hospital, Fulham Road, London, SW3 6JJ, UK.
Cellular DNA content is being recognised
increasingly as an important prognostic factor for
some solid tumours (Barlogie et al., 1983;
Friedlander et al., 1984a) but its influence on the
natural history of breast cancer is uncertain. Atkin
(1972), suggested that diploid breast cancers have a
significantly better eight year survival rate than
aneuploid tumours, while a more recent study has
shown that the majority of patients surviving 15
years or more from diagnosis had diploid or tetra-
ploid tumours, whereas most patients dying within
two years had tumours that were outside the
normal diploid range (Auer et al., 1984). Both of
these studies used static cytometry, which is much
less sensitive than flow cytometry for measuring
cellular DNA content. Until recently however, flow
cytometry required fresh, unfixed tissue as a
starting point, and this has hampered its
application in breast cancer, a disease often
characterised by recurrence many years after
original surgery.
We have now developed a technique whereby
paraffin-embedded tumour samples may be used for
flow cytometric analysis (Hedley et al., 1983), and
this has led to the possibility of retrospective
analysis of archival patient material. Furthermore,
it allows the selection of patients who were
investigated and treated in a standardised fashion,
for example, those entered into formal clinical trials
where these correlates are particularly well
documented. Using flow cytometric analysis of
paraffin-embedded material, we have examined the
possible influence of cellular DNA content on the
survival of patients with advanced breast cancer
receiving endocrine therapy, for whom sufficient
follow-up period had elapsed to enable survival to
be determined accurately.
Tumours studied were derived from patients with
symptomatic, locally recurrent or metastatic breast
cancer, entered onto one of two studies of
endocrine therapy at the Royal Marsden Hospital,
London. The first study was a randomised cross-
over comparison of tamoxifen and amino-
glutethimide combined with hydrocortisone; on
progression, or on relapse following response,
patients were crossed over to the second drug. In
the second study, patients received combination
endocrine therapy with tamoxifen, aminoglute-
thimide and hydrocortisone. Responses to therapy
in both studies were classified according to
standard U.I.C.C. criteria (Hayward et al., 1977)
and the clinical results of each have been described
elsewhere (Smith et al., 1982, 1983).
As it has been demonstrated previously that the
survival of patients achieving disease stabilisation
with endocrine therapy is similar to that of patients
achieving objective response (Harris et al., 1982),
patients classed as "no change" have been included
with patients classed as responders, for the
purposes of survival analysis. For patients in the
cross-over study, two response classifications were
available as two sequential treatments were used;
patients classified as "no change" or responding to
at least one of the treatments were included in the
group of responding patients.
The following clinical information was available
for all patients: Age, menopausal status at
diagnosis, interval between primary surgery and
recurrence (disease-free interval), dominant site of
disease, prior therapy, survival from entry to the
study (until death or date of last attendance), and
response to the various forms of endocrine therapy.
However, oestrogen receptor content of the
tumours was not available for any patient in this
series. Menopausal status was defined as follows:
postmenopausal, more than two years from the last
menstrual period; perimenopausal within two years
of the last menstrual period. Patients who presented
with advanced (inoperable) disease were classed as
having a disease-free interval of zero months.
Survival of patients with aneuploid or diploid
tumours was examined by life table analysis. The
Breslow version of the generalised Wilcoxon test
and also the logrank test were used to compare the
survival data for patients achieving stabilisation of
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disease or objective response with patients showing
disease progression on therapy.
Where possible, blocks from the primary tumour
were examined. However, if unavailable, blocks
from metastatic deposits were used as a valid
alternative as the DNA content of metastases has
been shown to correlate closely with that of the
primary (Auer et al., 1984). Histological sections
were cut from each block and examined to ensure
that tumour cells accounted for at least 10% of the
total cells in each section. Then, 30MM microtome
sections were cut and dewaxed by suspension in
xylene; the material was rehydrated in a sequence
of 100, 95, 70 and 50% ethanol, before washing in
distilled water. Sections were then resuspended in
0.5% pepsin (Sigma Chemical Co., USA) in 0.9%
NaCl solution (adjusted to pH 1.5 with 2N HCl)
and placed in a water bath at 37°C for 30min.
Nuclei were stained with 4', 6-diamidino-2-pheny-
lindol dichloride (1 jggml-1) (Boehringer, W.
Germany) in R.P.M.I. 1640 tissue culture medium.
Cellular DNA content was measured using an ICP
22 flow cytometer (Ortho-Instruments, USA), and
the results displayed as histograms of cellular DNA
content.
Using this technique all histograms contain a
peak corresponding to the G1 phase of diploid
cells. The presence of a second (or multiple) G1
peak was used to identify those tumours which
were aneuploid, i.e. contained a clone of cells with
an abnormal total DNA content. Our previous
studies using admixtures of aneuploid tumour cells
and normal human lymphocytes have shown that
the method is highly sensitive, able to detect the
presence of a minimum content of 1% aneuploid
tumour cells within a diploid population
(Friedlander et al., 1984b).
Of a total of 179 patients entered onto the two
studies, blocks were available for 21 patients from
each study. The block was from the primary
tumour in 23, skin metastases in 11, lymph node
metastasis in five, hepatic metastases in two and a
metastases to the small intestine in one.
Of the 42 tumour samples examined, 31 (74%)
were aneuploid and 11 (26%) diploid. Clinical
characteristics for the two groups are shown in
Table I. In the aneuploid group, a higher
proportion of patients were postmenopausal, and
visceral metastases appeared to be more common.
Ofthe patients with aneuploid tumours 13/31 (42%)
achieved objective response or disease stabilisation
compared with 2/11 (18%) of those with diploid
tumours (P=NS, Chi-square). The median survival
of patients with aneuploid tumours from entry to
the study was 19+ months (range 1-59+ months)
compared with 11 months (range 1-48 months) for
diploid tumours (P=NS, logrank test) (Figure 1).
Table I Clinical characteristics of patients classed as
having aneuploid or diploid tumours
Aneuploid Diploid
No. ofpatients 31 11
Age (years)
Range
Median
Objective response
No change
Progressive disease
Postmenopausal
Perimenopausal
Premenopausal
Disease free interval
(months)
Range
Mean
Median
Dominant site of disease
Local recurrence
Soft tissue
Bone
Visceral
Prior therapy
None
Endocrine therapy
Chemotherapy
Radiotherapy
Survival from study entry
Range
Median
Patients alive
1,
0
a.
35-73
52
8 (26%)
5 (16%)
18 (58%)
22 (71%)
3 (10%)
6 (19%)
0-96
18
11
8 (26%)
3 (10%)
9 (29%)
11 (35%)
17 (55%)
8 (26%)
5 (16%)
5 (16%)
29-71
50
1 (9%)
1 (9%)
9 (82%)
5 (45%)
6 (55%)
0-25
S
0
4 (36%)
3 (27%)
2 (18%)
2 (18%)
6 (55%)
0
4 (36%)
2 (18%)
1-59 months 1-48 months
19+ months 11 months
5 (16%) 0
-= Aneuploid (31)
= Diploid (11)
1 = Patient still alive
I.
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Figure 1 Life table analysis demonstrating survival
for patients with aneuploid or diploid tumours from
entry to the study.
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Figure 2 Life table analysis demonstrating survival
for patients with aneuploid or diploid tumours from
time of first recurrence or presentation of advanced
disease.
Median survival calculated from the date of first
recurrence was 32 months (range 1-59+ months)
for the aneuploid group and 26 months (range 5-48
months) for the diploid group (P=NS, logrank
test) (Figure 2). Five patients, all with aneuploid
tumours which responded to endocrine therapy, are
still surviving after a median of 51 + months from
the start of treatment.
Twenty-one patients with aneuploid tumours and
8 with diploid tumours received chemotherapy
subsequently. Objective responses were noted in 6
of the 21 aneuploid patients (29%) and one of the
diploid patients (13%). The median duration of
response to chemotherapy in the aneuploid group
was 10+ months while the duration of response for
the patient in the diploid group was 8+ months.
Of the 5 long term survivors, notably three remain
in remission and have not required chemotherapy
and of the two who received chemotherapy both
failed to achieve response.
To our knowledge, this is the first study to
investigate the possible relationship between tumour
ploidy, response to endocrine therapy and survival
in advanced breast cancer. Most previous flow
cytometry studies have noted that about 70-80%
(i.e. similar to the present series) of unselected
patients with breast cancer have aneuploid tumours
(Bichel et al., 1982; Olszewski et al., 1981; Raber et
al., 1982; Moran et al., 1982; Taylor et al., 1983;
Hedley et al., 1984).
The relationship between steroid hormone
receptor status and cellular DNA content is weak.
Although there is a trend for diploid tumours to be
oestrogen receptor positive, this fails to achieve
statistical significance in most studies (Taylor et al.,
1983; Olszewski et al., 1981; Kute et al., 1981;
Raber et al., 1982). Two studies have investigated
ploidy of breast cancers and survival and both have
suggested that patients with diploid tumours
survive longer than those with aneuploid tumours
(Atkin, 1972; Auer et al., 1984). However, both of
these studies used static cytometry, which is less
sensitive than the method used in the present series
and furthermore, the responsiveness of the tumours
to endocrine therapy was not studied in a
systematic fashion.
As expected, patients in the present study who
responded to endocrine therapy exhibited more
favourable prognostic factors such as a longer
median disease-free interval and the presence of
soft-tissue or bone disease rather than visceral
dominant disease, but, contrary to expectation these
features were more common in the patients with
aneuploid tumours. Moreover, no adverse clinical
features (such as the presence of inflammatory
carcinoma) could be identified in the diploid group
which might have influenced adversely the outcome
of these patients. Thus, we were unable to confirm
the previous suggestions that patients with diploid
tumours show either increased response to
hormonal manipulations or improved survival
compared with those with aneuploid tumours.
However, we readily acknowledge that the current
study describes a small number of patients and is of
low statistical power. For example, if diploid
tumours were truly associated with a higher
response rate to endocrine therapy (say 40%) than
aneuploid tumours (say 20%), then 230 patients
would need to be studied to have an 80% chance of
detecting this difference with a two-sided 5%
probability test. Nevertheless, in view of the trend
towards a more favourable outcome in the
aneuploid group (95% confidence intervals - 49%,
7%), based on the observed results, it seems highly
unlikely that the presence of a diploid tumour
confers a substantial advantage with respect to
response to endocrine therapy and survival.
However, only by studies with larger numbers of
patients will a statistically significant result be
obtained.
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